Kairos Pharma, LTD. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers the period ending September 16, 2024, for Kairos Pharma, LTD., a Delaware corporation and emerging growth company. The filing details the pricing and closing of the Company's initial public offering (IPO) of common stock on The Nasdaq Stock Market LLC under the trading symbol "KAPA".
Key Financial Metrics and Transaction Details
- Offering Price: $4.00 per share.
- Shares Sold: 1,550,000 shares of Common Stock.
- Gross Proceeds: $6,200,000 (before underwriting discounts, commissions, and offering expenses).
- Over-Allotment Option: Underwriters granted a 45-day option to purchase up to an additional 232,500 shares.
- Warrants Issued: Two warrants issued to underwriters for a total of 108,500 shares (54,250 each) at an exercise price of $4.80 per share (120% of IPO price).
- Warrant Terms: Exercisable between March 16, 2025, and September 17, 2029; includes cashless exercise provisions and anti-dilution protections.
Note: This filing does not provide data on revenue, profit, operating cash flow, margins, or existing debt levels, as it reports solely on the capital raising event.
Material Changes
The primary material change is the transition from a private entity to a public company listed on Nasdaq. The Company entered into a definitive underwriting agreement with Boustead Securities, LLC, and closed the transaction on September 17, 2024, resulting in the issuance of new equity and warrants.
Outlook, Risks, and Management Commentary
Management announced the closing of the IPO via a press release furnished as Exhibit 99.1. The filing highlights standard risks associated with the underwriting agreement and warrant terms, including potential dilution from the exercise of the over-allotment option and warrants. No specific forward-looking financial guidance or operational outlook is provided in this specific 8-K filing.
Investor Verification Checklist
- Verify the final net proceeds after deducting underwriting discounts and offering expenses.
- Confirm the utilization of the 45-day over-allotment option by underwriters.
- Review the full text of the Underwriting Agreement (Exhibit 1.1) for lock-up periods and specific underwriter obligations.
- Examine the Warrant agreements (Exhibits 4.1 and 4.2) for detailed anti-dilution adjustment formulas.
- Check subsequent filings for the Company's audited financial statements and use of proceeds.